{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:58:21Z","timestamp":1792486701839,"version":"4.5.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00774-023-01414-1","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T07:02:27Z","timestamp":1681110147000},"page":"307-316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-1953","authenticated-orcid":false,"given":"Shunji","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"1414_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2021.100355","volume":"28","author":"K Waqas","year":"2021","unstructured":"Waqas K, Lima Ferreira J, Tsourdi E et al (2021) Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol 28:100355","journal-title":"J Bone Oncol"},{"key":"1414_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"EBCTCG","year":"1998","unstructured":"EBCTCG (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet 351:1451\u20131467","journal-title":"Lancet"},{"key":"1414_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/jnci\/djn498","volume":"101","author":"A Hackshaw","year":"2009","unstructured":"Hackshaw A, Baum M, Fornander T et al (2009) Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 101:341\u2013349","journal-title":"J Natl Cancer Inst"},{"key":"1414_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","volume":"28","author":"M Dowsett","year":"2010","unstructured":"Dowsett M, Cuzick J, Ingle J et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509\u2013518","journal-title":"J Clin Oncol"},{"key":"1414_CR5","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines Breast Cancer Version 4.2022 - June 21, 2022. www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"key":"1414_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","volume":"19","author":"JG Klijn","year":"2001","unstructured":"Klijn JG, Blamey RW, Boccardo F et al (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343\u2013353","journal-title":"J Clin Oncol"},{"key":"1414_CR7","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra023246","volume":"348","author":"IE Smith","year":"2003","unstructured":"Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431\u20132442","journal-title":"N Engl J Med"},{"key":"1414_CR8","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Andre F et al (2020) Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395:817\u2013827","journal-title":"Lancet"},{"key":"1414_CR9","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.annonc.2021.09.015","volume":"32","author":"N Harbeck","year":"2021","unstructured":"Harbeck N, Rastogi P, Martin M et al (2021) Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 32:1571\u20131581","journal-title":"Ann Oncol"},{"key":"1414_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","volume":"14","author":"TJ Powles","year":"1996","unstructured":"Powles TJ, Hickish T, Kanis JA et al (1996) Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78\u201384","journal-title":"J Clin Oncol"},{"key":"1414_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100254","volume":"18","author":"U Stumpf","year":"2019","unstructured":"Stumpf U, Kostev K, Kyvernitakis J et al (2019) Incidence of fractures in young women with breast cancer\u2014a retrospective cohort study. J Bone Oncol 18:100254","journal-title":"J Bone Oncol"},{"key":"1414_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1404037","volume":"371","author":"O Pagani","year":"2014","unstructured":"Pagani O, Regan MM, Walley BA et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107\u2013118","journal-title":"N Engl J Med"},{"key":"1414_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","volume":"69","author":"P Hadji","year":"2009","unstructured":"Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69:73\u201382","journal-title":"Crit Rev Oncol Hematol"},{"key":"1414_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","volume":"26","author":"R Eastell","year":"2008","unstructured":"Eastell R, Adams JE, Coleman RE et al (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26:1051\u20131057","journal-title":"J Clin Oncol"},{"key":"1414_CR15","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1056\/NEJMoa0810818","volume":"361","author":"H Mouridsen","year":"2009","unstructured":"BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A et al (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766\u2013776","journal-title":"N Engl J Med"},{"key":"1414_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","volume":"8","author":"RE Coleman","year":"2007","unstructured":"Coleman RE, Banks LM, Girgis SI et al (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the intergroup exemestane study (IES): a randomised controlled study. Lancet Oncol 8:119\u2013127","journal-title":"Lancet Oncol"},{"key":"1414_CR17","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/jnci\/djr242","volume":"103","author":"E Amir","year":"2011","unstructured":"Amir E, Seruga B, Niraula S et al (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1299\u20131309","journal-title":"J Natl Cancer Inst"},{"key":"1414_CR18","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e403","volume":"35","author":"YK Lee","year":"2020","unstructured":"Lee YK, Lee EG, Kim HY et al (2020) Osteoporotic fractures of the spine, hip, and other locations after adjuvant endocrine therapy with aromatase inhibitors in breast cancer patients: a meta-analysis. J Korean Med Sci 35:e403","journal-title":"J Korean Med Sci"},{"key":"1414_CR19","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135\u20131141","journal-title":"Lancet Oncol"},{"key":"1414_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jnci\/djx141","volume":"110","author":"H Goldvaser","year":"2018","unstructured":"Goldvaser H, Barnes TA, \u0160eruga B et al (2018) Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 110:31\u201339","journal-title":"J Natl Cancer Inst"},{"key":"1414_CR21","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","volume":"22","author":"A Sverrisdottir","year":"2004","unstructured":"Sverrisdottir A, Fornander T, Jacobsson H et al (2004) Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22:3694\u20133699","journal-title":"J Clin Oncol"},{"key":"1414_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00198-014-2955-3","volume":"26","author":"M Kalder","year":"2015","unstructured":"Kalder M, Kyvernitakis I, Albert US et al (2015) Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy. Osteoporos Int 26:353\u2013360","journal-title":"Osteoporos Int"},{"key":"1414_CR23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840\u2013849","journal-title":"Lancet Oncol"},{"key":"1414_CR24","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.3390\/ijms23052477","volume":"23","author":"M Iuliani","year":"2022","unstructured":"Iuliani M, Simonetti S, Ribelli G et al (2022) Biological effects of cyclin-dependent kinase inhibitors ribociclib, palbociclib and abemaciclib on breast cancer bone microenvironment. Int J Mol Sci 23:2477","journal-title":"Int J Mol Sci"},{"key":"1414_CR25","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/annonc\/mdj128","volume":"17","author":"K Yoneda","year":"2006","unstructured":"Yoneda K, Tanji Y, Okishiro M et al (2006) Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: is there a racial difference? Ann Oncol 17:1175\u20131176","journal-title":"Ann Oncol"},{"key":"1414_CR26","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1159\/000323489","volume":"79","author":"T Aihara","year":"2010","unstructured":"Aihara T, Suemasu K, Takei H et al (2010) Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy. Oncology 79:376\u2013381","journal-title":"Oncology"},{"key":"1414_CR27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10549-012-1973-0","volume":"133","author":"S Takahashi","year":"2012","unstructured":"Takahashi S, Iwase T, Kohno N et al (2012) Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Res Treat 133:685\u2013693","journal-title":"Breast Cancer Res Treat"},{"key":"1414_CR28","doi-asserted-by":"publisher","first-page":"T19","DOI":"10.1530\/ERC-21-0098","volume":"28","author":"N Mitsiades","year":"2021","unstructured":"Mitsiades N, Kaochar S (2021) Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer. Endocr Relat Cancer 28:T19\u2013T38","journal-title":"Endocr Relat Cancer"},{"key":"1414_CR29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2147\/CIA.S115472","volume":"11","author":"NV Mohamad","year":"2016","unstructured":"Mohamad NV, Soelaiman IN, Chin KY (2016) A concise review of testosterone and bone health. Clin Interv Aging 11:1317\u20131324","journal-title":"Clin Interv Aging"},{"key":"1414_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","volume":"163","author":"HW Daniell","year":"2000","unstructured":"Daniell HW, Dunn SR, Ferguson DW et al (2000) Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163:181\u2013186","journal-title":"J Urol"},{"key":"1414_CR31","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","volume":"87","author":"D Mittan","year":"2002","unstructured":"Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87:3656\u20133661","journal-title":"J Clin Endocrinol Metab"},{"key":"1414_CR32","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","volume":"167","author":"A Berruti","year":"2002","unstructured":"Berruti A, Dogliotti L, Terrone C et al (2002) Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167:2361\u20132367","journal-title":"J Urol"},{"key":"1414_CR33","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","volume":"22","author":"MR Smith","year":"2004","unstructured":"Smith MR, Goode M, Zietman AL et al (2004) Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 22:2546\u20132553","journal-title":"J Clin Oncol"},{"key":"1414_CR34","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1097\/01.ju.0000127738.94221.da","volume":"171","author":"PR Sieber","year":"2004","unstructured":"Sieber PR, Keiller DL, Kahnoski RJ et al (2004) Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 171:2272\u20132276","journal-title":"J Urol"},{"key":"1414_CR35","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/S0022-5347(05)00999-7","volume":"175","author":"J Morote","year":"2006","unstructured":"Morote J, Orsola A, Abascal JM et al (2006) Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 175:1679\u20131683","journal-title":"J Urol"},{"key":"1414_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","volume":"57","author":"BJ Kiratli","year":"2001","unstructured":"Kiratli BJ, Srinivas S, Perkash I et al (2001) Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57:127\u2013132","journal-title":"Urology"},{"key":"1414_CR37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL et al (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154\u2013164","journal-title":"N Engl J Med"},{"key":"1414_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00198-018-4722-3","volume":"30","author":"M Wallander","year":"2019","unstructured":"Wallander M, Axelsson KF, Lundh D et al (2019) Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO). Osteoporos Int 30:115\u2013125","journal-title":"Osteoporos Int"},{"key":"1414_CR39","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Lee WC, Brandman J et al (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23:7897\u20137903","journal-title":"J Clin Oncol"},{"key":"1414_CR40","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/pcan.2014.31","volume":"17","author":"AK Morgans","year":"2014","unstructured":"Morgans AK, Fan KH, Koyama T et al (2014) Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study. Prostate Cancer Prostatic Dis 17:338\u2013342","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1414_CR41","doi-asserted-by":"publisher","first-page":"12520","DOI":"10.18632\/oncotarget.3724","volume":"6","author":"M Iuliani","year":"2015","unstructured":"Iuliani M, Pantano F, Buttigliero C et al (2015) Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget 6:12520\u201312528","journal-title":"Oncotarget"},{"key":"1414_CR42","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.21873\/invivo.12167","volume":"34","author":"S Nakajima","year":"2020","unstructured":"Nakajima S, Inoue T, Huang M et al (2020) Does the addition of abiraterone to castration affect the reduction in bone mineral density? In Vivo 34:3291\u20133299","journal-title":"In Vivo"},{"key":"1414_CR43","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1210\/en.2015-1566","volume":"157","author":"J Wu","year":"2016","unstructured":"Wu J, Mov\u00e9rare-Skrtic S, B\u00f6rjesson AE et al (2016) Enzalutamide reduces the bone mass in the axial but not the appendicular skeleton in male mice. Endocrinology 157:969\u2013977","journal-title":"Endocrinology"},{"key":"1414_CR44","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378:1408\u20131418","journal-title":"N Engl J Med"},{"key":"1414_CR45","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL et al (2019) Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380:1235\u20131246","journal-title":"N Engl J Med"},{"key":"1414_CR46","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378:2465\u20132474","journal-title":"N Engl J Med"},{"key":"1414_CR47","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.urology.2009.01.046","volume":"73","author":"K Izumi","year":"2009","unstructured":"Izumi K, Mizokami A, Sugimoto K et al (2009) Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 73:1342\u20131346","journal-title":"Urology"},{"key":"1414_CR48","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1002\/cncr.24404","volume":"115","author":"T Satoh","year":"2009","unstructured":"Satoh T, Kimura M, Matsumoto K et al (2009) Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer 115:3468\u20133474","journal-title":"Cancer"},{"key":"1414_CR49","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11657-013-0166-8","volume":"9","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, Johansson H, Oden A et al (2014) Worldwide uptake of FRAX. Arch Osteoporos 9:166","journal-title":"Arch Osteoporos"},{"key":"1414_CR50","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/jbmr.3726","volume":"34","author":"WD Leslie","year":"2019","unstructured":"Leslie WD, Morin SN, Lix LM et al (2019) Performance of FRAX in women with breast cancer initiating aromatase inhibitor therapy: a registry-based cohort study. J Bone Miner Res 34:1428\u20131435","journal-title":"J Bone Miner Res"},{"key":"1414_CR51","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1634\/theoncologist.2012-0051","volume":"17","author":"M Datta","year":"2012","unstructured":"Datta M, Schwartz GG (2012) Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review. Oncologist 17:1171\u20131179","journal-title":"Oncologist"},{"key":"1414_CR52","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00198-017-4237-3","volume":"29","author":"J Dalla Via","year":"2018","unstructured":"Dalla Via J, Daly RM, Fraser SF (2018) The effect of exercise on bone mineral density in adult cancer survivors: a systematic review and meta-analysis. Osteoporos Int 29:287\u2013303","journal-title":"Osteoporos Int"},{"key":"1414_CR53","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/bjc.1997.105","volume":"75","author":"T Saarto","year":"1997","unstructured":"Saarto T, Blomqvist C, Valimaki M et al (1997) Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 75:602\u2013605","journal-title":"Br J Cancer"},{"key":"1414_CR54","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","volume":"15","author":"PD Delmas","year":"1997","unstructured":"Delmas PD, Balena R, Confravreux E et al (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15:955\u2013962","journal-title":"J Clin Oncol"},{"key":"1414_CR55","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","volume":"28","author":"C Van Poznak","year":"2010","unstructured":"Van Poznak C, Hannon RA, Mackey JR et al (2010) Prevention of aromatase inhibitor\u2013induced bone loss using risedronate: the SABRE trial. J Clin Oncol 28:967\u2013975","journal-title":"J Clin Oncol"},{"key":"1414_CR56","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00198-015-3100-7","volume":"26","author":"SL Greenspan","year":"2015","unstructured":"Greenspan SL, Vujevich KT, Brufsky A et al (2015) Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial. Osteoporos Int 26:1857\u20131864","journal-title":"Osteoporos Int"},{"key":"1414_CR57","doi-asserted-by":"publisher","first-page":"R24","DOI":"10.1186\/bcr2565","volume":"12","author":"C Markopoulos","year":"2010","unstructured":"Markopoulos C, Tzoracoleftherakis E, Polychronis A et al (2010) Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 12:R24","journal-title":"Breast Cancer Res"},{"key":"1414_CR58","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1507\/endocrj.EJ12-0283","volume":"60","author":"Y Rhee","year":"2013","unstructured":"Rhee Y, Song K, Park S et al (2013) Efficacy of a combined alendronate and calcitriol agent (Maxmarvil\u00ae) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. Endocr J 60:167\u2013172","journal-title":"Endocr J"},{"key":"1414_CR59","doi-asserted-by":"publisher","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","volume":"14","author":"JE Lester","year":"2008","unstructured":"Lester JE, Dodwell D, Purohit OP et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336\u20136342","journal-title":"Clin Cancer Res"},{"key":"1414_CR60","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2018.12.005","volume":"108","author":"L Livi","year":"2019","unstructured":"Livi L, Scotti V, Desideri I et al (2019) Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. Eur J Cancer 108:100\u2013110","journal-title":"Eur J Cancer"},{"key":"1414_CR61","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","volume":"9","author":"AM Brufsky","year":"2009","unstructured":"Brufsky AM, Bosserman LD, Caradonna RR et al (2009) Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77\u201385","journal-title":"Clin Breast Cancer"},{"key":"1414_CR62","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, de Boer R, Eidtmann H et al (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24:398\u2013405","journal-title":"Ann Oncol"},{"key":"1414_CR63","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","volume":"12","author":"A Llombart","year":"2012","unstructured":"Llombart A, Frassoldati A, Paija O et al (2012) Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 12:40\u201348","journal-title":"Clin Breast Cancer"},{"key":"1414_CR64","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000334456","volume":"81","author":"T Safra","year":"2011","unstructured":"Safra T, Bernstein-Molho R, Greenberg J et al (2011) The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. Oncology 81:298\u2013305","journal-title":"Oncology"},{"key":"1414_CR65","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","volume":"117","author":"SL Hines","year":"2009","unstructured":"Hines SL, Mincey B, Dentchev T et al (2009) Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 117:603\u2013609","journal-title":"Breast Cancer Res Treat"},{"key":"1414_CR66","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1002\/cncr.29327","volume":"121","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston ND, Sloan JA, Liu H et al (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537\u20132543","journal-title":"Cancer"},{"key":"1414_CR67","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/625060","volume":"2014","author":"PP Anagha","year":"2014","unstructured":"Anagha PP, Sen S (2014) The efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss for postmenopausal women with early breast cancer: a systematic review and meta-analysis. J Oncol 2014:625060","journal-title":"J Oncol"},{"key":"1414_CR68","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875\u20134882","journal-title":"J Clin Oncol"},{"key":"1414_CR69","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433\u2013443","journal-title":"Lancet"},{"key":"1414_CR70","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00774-018-0917-0","volume":"37","author":"K Nakatsukasa","year":"2019","unstructured":"Nakatsukasa K, Koyama H, Ouchi Y et al (2019) Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer. J Bone Miner Metab 37:301\u2013306","journal-title":"J Bone Miner Metab"},{"key":"1414_CR71","doi-asserted-by":"publisher","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Nelson JB, Trump DL et al (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146:416\u2013424","journal-title":"Ann Intern Med"},{"key":"1414_CR72","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.eururo.2012.09.007","volume":"63","author":"LH Klotz","year":"2013","unstructured":"Klotz LH, McNeill IY, Kebabdjian M et al (2013) A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprolide (CORAL) study. Eur Urol 63:927\u2013935","journal-title":"Eur Urol"},{"key":"1414_CR73","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1056\/NEJMoa010845","volume":"345","author":"MR Smith","year":"2001","unstructured":"Smith MR, McGovern FJ, Zietman AL et al (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948\u2013955","journal-title":"N Engl J Med"},{"key":"1414_CR74","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.ijrobp.2012.11.007","volume":"85","author":"R Choo","year":"2013","unstructured":"Choo R, Lukka H, Cheung P et al (2013) Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. Int J Radiat Oncol Biol Phys 85:1239\u20131245","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1414_CR75","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"MR Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason DM et al (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008\u20132012","journal-title":"J Urol"},{"key":"1414_CR76","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","volume":"25","author":"MD Michaelson","year":"2007","unstructured":"Michaelson MD, Kaufman DS, Lee H et al (2007) Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25:1038\u20131042","journal-title":"J Clin Oncol"},{"key":"1414_CR77","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.juro.2006.04.078","volume":"176","author":"CW Ryan","year":"2006","unstructured":"Ryan CW, Huo D, Demers LM et al (2006) Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 176:972\u2013978","journal-title":"J Urol"},{"key":"1414_CR78","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/j.juro.2009.07.046","volume":"182","author":"N Bhoopalam","year":"2009","unstructured":"Bhoopalam N, Campbell SC, Moritz T et al (2009) Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol 182:2257\u20132264","journal-title":"J Urol"},{"key":"1414_CR79","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hernandez Toriz N et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745\u2013755","journal-title":"N Engl J Med"},{"key":"1414_CR80","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1210\/jc.2003-032058","volume":"89","author":"MR Smith","year":"2004","unstructured":"Smith MR, Fallon MA, Lee H et al (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841\u20133846","journal-title":"J Clin Endocrinol Metab"},{"key":"1414_CR81","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","volume":"179","author":"MR Smith","year":"2008","unstructured":"Smith MR, Malkowicz SB, Chu F et al (2008) Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 179:152\u2013155","journal-title":"J Urol"},{"key":"1414_CR82","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2018.02.004","volume":"94","author":"C Wilson","year":"2018","unstructured":"Wilson C, Bell R, Hinsley S et al (2018) Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01\/04) study. Eur J Cancer 94:70\u201378","journal-title":"Eur J Cancer"},{"key":"1414_CR83","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1634\/theoncologist.2012-0261","volume":"18","author":"A Valachis","year":"2013","unstructured":"Valachis A, Polyzos NP, Coleman RE et al (2013) Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 18:353\u2013361","journal-title":"Oncologist"},{"key":"1414_CR84","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/pcan.2011.4","volume":"15","author":"A Serpa Neto","year":"2012","unstructured":"Serpa Neto A, Tobias-Machado M, Esteves MA et al (2012) Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 15:36\u201344","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1414_CR85","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.juro.2010.06.022","volume":"184","author":"MR Smith","year":"2010","unstructured":"Smith MR, Morton RA, Barnette KG et al (2010) Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 184:1316\u20131321","journal-title":"J Urol"},{"key":"1414_CR86","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1677\/erc.1.01094","volume":"13","author":"M Caraglia","year":"2006","unstructured":"Caraglia M, Santini D, Marra M et al (2006) Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 13:7\u201326","journal-title":"Endocr Relat Cancer"},{"key":"1414_CR87","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature09495","volume":"468","author":"E Gonzalez-Suarez","year":"2010","unstructured":"Gonzalez-Suarez E, Jacob AP, Jones J et al (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468:103\u2013107","journal-title":"Nature"},{"key":"1414_CR88","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","volume":"365","author":"RE Coleman","year":"2011","unstructured":"Coleman RE, Marshall H, Cameron D et al (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396\u20131405","journal-title":"N Engl J Med"},{"key":"1414_CR89","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386:1353\u20131361","journal-title":"Lancet"},{"key":"1414_CR90","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/jnci\/djz215","volume":"112","author":"JR Gralow","year":"2020","unstructured":"Gralow JR, Barlow WE, Paterson AHG et al (2020) Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307. J Natl Cancer Inst 112:698\u2013707","journal-title":"J Natl Cancer Inst"},{"key":"1414_CR91","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1001\/jamaoncol.2021.1854","volume":"7","author":"TWP Friedl","year":"2021","unstructured":"Friedl TWP, Fehm T, M\u00fcller V et al (2021) Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment: a phase 3 randomized clinical trial. JAMA Oncol 7:1149\u20131157","journal-title":"JAMA Oncol"},{"key":"1414_CR92","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","volume":"21","author":"R Coleman","year":"2020","unstructured":"Coleman R, Finkelstein DM, Barrios C et al (2020) Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 21:60\u201372","journal-title":"Lancet Oncol"},{"key":"1414_CR93","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.21.02647","volume":"40","author":"A Eisen","year":"2022","unstructured":"Eisen A, Somerfield MR, Accordino MK et al (2022) Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. J Clin Oncol 40:787\u2013800","journal-title":"J Clin Oncol"},{"key":"1414_CR94","doi-asserted-by":"publisher","first-page":"96","DOI":"10.14310\/horm.2002.1226","volume":"8","author":"PD Papapetrou","year":"2009","unstructured":"Papapetrou PD (2009) Bisphosphonate-associated adverse events. Hormones (Athens) 8:96\u2013110","journal-title":"Hormones (Athens)"},{"key":"1414_CR95","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/DHPS.S7727","volume":"3","author":"EM Lewiecki","year":"2011","unstructured":"Lewiecki EM (2011) Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. Drug Healthc Patient Saf 3:79\u201391","journal-title":"Drug Healthc Patient Saf"},{"key":"1414_CR96","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00198-015-3335-3","volume":"27","author":"A Khan","year":"2016","unstructured":"Khan A, Morrison A, Cheung A et al (2016) Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int. 27:853\u2013859","journal-title":"Osteoporos Int."},{"key":"1414_CR97","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347","journal-title":"Ann Oncol"},{"key":"1414_CR98","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT et al (2003) American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042\u20134057","journal-title":"J Clin Oncol"},{"key":"1414_CR99","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","volume":"19","author":"P Hadji","year":"2008","unstructured":"Hadji P, Body JJ, Aapro MS et al (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19:1407\u20131416","journal-title":"Ann Oncol"},{"key":"1414_CR100","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ et al (2020) Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol 31:1650\u20131663","journal-title":"Ann Oncol"},{"key":"1414_CR101","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00774-020-01087-0","volume":"38","author":"S Fukumoto","year":"2020","unstructured":"Fukumoto S, Soen S, Taguchi T et al (2020) Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR. J Bone Miner Metab 38:141\u2013144","journal-title":"J Bone Miner Metab"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-023-01414-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-023-01414-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-023-01414-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T05:05:29Z","timestamp":1685336729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-023-01414-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1414"],"URL":"https:\/\/doi.org\/10.1007\/s00774-023-01414-1","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"30 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}